Get started

Signalspackage

SCHW The Charles Schwab Corporation Options Ahead of EarningsIf you haven`t sold SCHW before the sell-off: Now analyzing the options chain and the chart patterns of SCHW The Charles Schwab Corporation prior to the earnings report this week, I would consider purchasing the 92.5usd strike price Calls with an expiration date of 2026-1-16, for a premium of approximately $7.15. If these options prove to be profitable prior to the earnings release, I would sell at least half of them. Disclosure: I am part of Trade Nation's Influencer program and receive a monthly fee for using their TradingView charts in my analysis.
TRADENATION:SCHWLong
by TopgOptions
VKTX: Unusual Options Flow & a Breakthrough Weight-Loss DrugIf you haven`t bought CKTX before the recent rally: Now you need to know that Viking Therapeutics (VKTX) is a speculative biotech stock in the GLP-1/GIP agonist space, aiming to challenge market leaders like Eli Lilly and Novo Nordisk. Recently, I noticed unusual options flow — specifically, Jan 16, 2026 $60 strike calls Key Bullish Points 1) Riding the Obesity Drug Boom VK2735 is Viking’s dual agonist candidate showing promising early weight-loss efficacy, with potential overlap benefits in NASH (liver disease). The obesity treatment space is expected to exceed $100B by 2030—huge upside if their trials continue positively. 2) Options Flow Tells a Story Those Jan 2026 $60 calls caught my attention precisely because the stock currently trades in the mid-$60s. These aren’t cheap lottery plays—they’re strategically timed wrt trial readouts, partnerships, or acquisition interest. Essentially, someone anticipates meaningful upside in the near future. 3) Descending Wedge — Chart Looks Bullish VKTX peaked near $100, then pulled back into a well-defined descending wedge. If it breaks out above $70–$72 with volume, that could kick off a classic reversal trade. Smart Money Options Flow — Near-Term Bet: Recently, I spotted unusual open interest in $60 strike calls expiring Jan 16, 2026 — that’s only about 7 months away. This means someone is positioning for a big upside move relatively soon, likely betting on positive Phase 2b/3 data, a partnership deal, or even buyout chatter within the next few quarters. Short-dated, out-of-the-money call flow like this often hints at near-term news — not just a long-dated hedge.
NASDAQ:VKTXLong
by TopgOptions
Why BABA Alibaba Could Rebound Strongly by Year-End 2025If you haven`t bought BABA before the recent rally: What you need to know: BABA’s fundamentals, fueled by e-commerce, cloud, and AI, support its technical bullishness: E-commerce and Cloud Rebound: Q1 2025 revenue grew 7% year-over-year, with Taobao/Tmall rebounding and cloud revenue surging due to AI demand. Alibaba’s cloud division, China’s largest, benefits from hyperscaler AI workloads, with 15% profit margin projections by 2029. AI Leadership: BABA’s AI assistant and generative AI tools drove a 70% stock surge in early 2025, positioning it as a leader in China’s AI race. At 12x forward P/E with 8% revenue CAGR, BABA is undervalued (fair value ~$162). Share Buybacks: Aggressive share repurchasing (6% annual reduction) boosts EPS, with $1 trillion GMV reinforcing e-commerce dominance. Macro Tailwinds: Easing CCP regulations and China’s stimulus measures (e.g., rate cuts) support BABA’s rally. Minimal U.S. exposure insulates BABA from trade war risks. Conclusion: BABA’s Path to $168 BABA’s technicals, with a bullish breaker and wedge, signal a breakout above $125–$130, targeting $150–$168 by year-end 2025. Fundamentally, its e-commerce dominance, cloud/AI growth, and undervaluation make it a standout. Traders should buy dips near $110–$115 or await a $130 breakout. With stimulus and buybacks as catalysts, BABA is set to soar. Disclosure: I am part of Trade Nation's Influencer program and receive a monthly fee for using their TradingView charts in my analysis.
TRADENATION:BABALong
by TopgOptions
SNAP Upside PotentialIf you haven`t bought SNAP before the previous earnings: SNAP Key Fundamental Strengths in Q1 2025: Metric Q1 2025 Result Year-over-Year Change Revenue $1.36 billion +14% Daily Active Users (DAU) 460 million +9% Monthly Active Users (MAU) 900 million+ Net Loss $140 million -54% (improved) Adjusted EBITDA $108 million +137% Operating Cash Flow $152 million +72% Free Cash Flow $114 million +202% SNAP strong fundamental performance in Q1 2025, marked by accelerating revenue growth, expanding user engagement, sharply improving profitability, and robust cash flow generation, sets a solid foundation for a potential stock rally this year. The company’s innovation in AR, diversified revenue streams, and healthy balance sheet further support a bullish outlook. Investors focusing on fundamentals can view Snap as a growth stock with improving financial health and significant upside potential in 2025. My price target is $14. Disclosure: I am part of Trade Nation's Influencer program and receive a monthly fee for using their TradingView charts in my analysis.
TRADENATION:SNAPLong
by TopgOptions
TEAM Atlassian Corporation Options Ahead of EarningsIf you haven`t sold TEAM on this top: Now analyzing the options chain and the chart patterns of TEAM Atlassian Corporation prior to the earnings report this week, I would consider purchasing the 245usd strike price Calls with an expiration date of 2025-5-2, for a premium of approximately $8.70. If these options prove to be profitable prior to the earnings release, I would sell at least half of them. Disclosure: I am part of Trade Nation's Influencer program and receive a monthly fee for using their TradingView charts in my analysis.
TRADENATION:TEAMLong
by TopgOptions
NVDA NVIDIA Price Target by Year-EndNVIDIA Corporation (NVDA) remains a dominant force in the AI and semiconductor markets, with its forward price-to-earnings (P/E) ratio currently at 19.37—a reasonable valuation considering its growth trajectory and market position. NVIDIA’s leadership in the AI sector, particularly through its cutting-edge GPUs, has driven strong demand from data centers, cloud providers, and AI developers. The company’s recent product launches, including the Hopper and Blackwell architectures, have further solidified its competitive edge. Despite recent market volatility, NVIDIA's consistent revenue growth and expanding profit margins support the bullish case. The current P/E of 19.37 reflects a balanced risk-reward profile, suggesting that the stock is not overvalued despite its impressive performance. A price target of $145 by year-end reflects approximately 15% upside from current levels, driven by sustained AI demand and growing market penetration. Investors should watch for quarterly earnings reports and updates on AI chip demand, as these will likely act as key catalysts for upward momentum.
NASDAQ:NVDALong
by TopgOptions
MRNA Moderna Among My Top 10 Picks for 2025 | Price TargetIf you haven`t bought MRNA on the recent breakout: My price target for MRNA in 2025 is $55, driven by the following fundamental factors: Innovative mRNA Technology and Expanding Pipeline: Moderna has established itself as a leader in mRNA technology, initially gaining prominence through its COVID-19 vaccine. The company is now leveraging this innovative platform to develop a diverse array of therapeutic candidates, with approximately 40 development projects in progress across various fields, including infectious diseases, oncology, and rare genetic disorders. This broad pipeline not only enhances Moderna's potential for future revenue but also positions it to capitalize on emerging healthcare needs as the demand for advanced therapies continues to rise. Projected Revenue Growth: Despite facing financial challenges, including recent losses, Moderna's revenue outlook remains promising. The company is forecasting sales between $2.5 billion and $3.5 billion for 2025, which analysts believe could be conservative given the anticipated rollout of new vaccines and treatments. If successful, these products could significantly boost sales and profitability, driving investor confidence and stock price appreciation 16. Market projections suggest that if Moderna successfully navigates its clinical trials and product launches, the stock could reach around $80 per share by 2025. Strategic Partnerships and Collaborations: Moderna's strategic collaborations with major pharmaceutical companies enhance its development capabilities and market access. These partnerships are crucial for accelerating product development and increasing the adoption of its mRNA technology across various therapeutic areas. By aligning with established players in the industry, Moderna can leverage additional resources and expertise to bring its innovations to market more effectively. Market Sentiment and Recovery Potential: Currently trading at lower valuations due to past performance fluctuations, Moderna's stock is positioned for recovery as investor sentiment shifts with positive developments in its pipeline. The company's five-year growth trajectory shows resilience despite recent setbacks, indicating potential for a rebound as new products come to market. Analysts remain optimistic about Moderna's long-term prospects, suggesting that as the market recognizes the value of its innovative therapies, the stock could see substantial gains.
NASDAQ:MRNALong
by TopgOptions
3